` 000756 (Shandong Xinhua Pharmaceutical Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

000756
vs
Shanghai Composite

Over the past 12 months, has underperformed Shanghai Composite, delivering a return of -5% compared to the Shanghai Composite's 10% growth.

Stocks Performance
000756 vs Shanghai Composite

Loading

Performance Gap
000756 vs Shanghai Composite

Loading
000756
Shanghai Composite
Difference

Performance By Year
000756 vs Shanghai Composite

Loading
000756
Shanghai Composite
Add Stock

Competitors Performance
Shandong Xinhua Pharmaceutical Co Ltd vs Peers

Shanghai Composite
000756
LLY
JNJ
NOVO B
ROG
Add Stock

Shandong Xinhua Pharmaceutical Co Ltd
Glance View

Market Cap
7.5B CNY
Industry
Pharmaceuticals

In the industrious province of Shandong, China, Shandong Xinhua Pharmaceutical Co. Ltd. emerges as a notable player in the pharmaceutical landscape. Established in 1943, the company has grown into a comprehensive pharmaceutical enterprise with a significant presence both domestically and internationally. At its core, Shandong Xinhua is devoted to the research, development, and manufacture of active pharmaceutical ingredients (APIs), finished dosages, and chemical intermediates. The firm's strength lies in its diverse range of products, with pain management and anti-infectives being standout categories. Their strategic focus on innovation is evident in their state-of-the-art R&D facilities, which fuel continuous product development, ensuring they meet high regulatory standards and cater to evolving market demands. The journey of Shandong Xinhua is one of strategic evolution, with a steadfast commitment to quality and sustainability. This narrative is reflected in their robust revenue streams derived from both domestic sales and the lucrative export markets across over 50 countries. The company's business model hinges on creating value through efficient manufacturing processes and leveraging economies of scale, which enhances their competitive edge in the global market. With an eye on future growth, they've also been investing in digitalization to streamline operations and enhance productivity. As the pharmaceutical sector continues to expand, Shandong Xinhua Pharmaceutical Co. Ltd. is poised to capitalize on emerging opportunities, underpinned by its solid foundation and innovative thrust.

Intrinsic Value
19.52 CNY
Undervaluation 22%
Intrinsic Value
Price
Back to Top